Recent resignation of FDA Commissioner Marty Makary has elevated Kyle Diamantas, the agency's Deputy Commissioner for Food now serving as acting head, to frontrunner status in trader pricing. Trump's direct Truth Social endorsement of Diamantas for the interim role, combined with his legal-policy background and ties to administration figures, has concentrated market expectations around a permanent nomination for him. Former Commissioner Stephen Hahn and ex-acting head Brett Giroir remain distant alternatives due to prior service records, while Sara Brenner and Grace Graham trail on limited public signals. The low probability assigned to no announcement by year-end reflects the administration's ongoing search for a confirmed successor amid standard Senate confirmation processes.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วKyle Diamantas 67%
Stephen Hahn 7%
Brett Giroir 3.8%
Sara Brenner 3.3%
ใหม่
ใหม่
Dec 31, 2026
Kyle Diamantas
52%
Stephen Hahn
7%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
1%
Kyle Diamantas 67%
Stephen Hahn 7%
Brett Giroir 3.8%
Sara Brenner 3.3%
ใหม่
ใหม่
Dec 31, 2026
Kyle Diamantas
$1,359 ปริมาณ
52%
Stephen Hahn
$975 ปริมาณ
7%
Brett Giroir
$1,510 ปริมาณ
4%
Grace Graham
$1,842 ปริมาณ
3%
Sara Brenner
$848 ปริมาณ
3%
No announcement by December 31
$425 ปริมาณ
1%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent resignation of FDA Commissioner Marty Makary has elevated Kyle Diamantas, the agency's Deputy Commissioner for Food now serving as acting head, to frontrunner status in trader pricing. Trump's direct Truth Social endorsement of Diamantas for the interim role, combined with his legal-policy background and ties to administration figures, has concentrated market expectations around a permanent nomination for him. Former Commissioner Stephen Hahn and ex-acting head Brett Giroir remain distant alternatives due to prior service records, while Sara Brenner and Grace Graham trail on limited public signals. The low probability assigned to no announcement by year-end reflects the administration's ongoing search for a confirmed successor amid standard Senate confirmation processes.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: May 12, 2026, 7:59 PM ET
ปริมาณการซื้อขาย
$6,898วันสิ้นสุด
Dec 31, 2026ตลาดเปิดเมื่อ
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent resignation of FDA Commissioner Marty Makary has elevated Kyle Diamantas, the agency's Deputy Commissioner for Food now serving as acting head, to frontrunner status in trader pricing. Trump's direct Truth Social endorsement of Diamantas for the interim role, combined with his legal-policy background and ties to administration figures, has concentrated market expectations around a permanent nomination for him. Former Commissioner Stephen Hahn and ex-acting head Brett Giroir remain distant alternatives due to prior service records, while Sara Brenner and Grace Graham trail on limited public signals. The low probability assigned to no announcement by year-end reflects the administration's ongoing search for a confirmed successor amid standard Senate confirmation processes.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$6,898วันสิ้นสุด
Dec 31, 2026ตลาดเปิดเมื่อ
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Recent resignation of FDA Commissioner Marty Makary has elevated Kyle Diamantas, the agency's Deputy Commissioner for Food now serving as acting head, to frontrunner status in trader pricing. Trump's direct Truth Social endorsement of Diamantas for the interim role, combined with his legal-policy background and ties to administration figures, has concentrated market expectations around a permanent nomination for him. Former Commissioner Stephen Hahn and ex-acting head Brett Giroir remain distant alternatives due to prior service records, while Sara Brenner and Grace Graham trail on limited public signals. The low probability assigned to no announcement by year-end reflects the administration's ongoing search for a confirmed successor amid standard Senate confirmation processes.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย